Pharmaceutical Investing Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
Pharmaceutical Investing Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
Pharmaceutical Investing Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
Pharmaceutical Investing Pfizer's BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
Pharmaceutical Investing Hearing Against Pfizer Set For 30 May In Contraceptive 'Depo-Provera' Multidistrict Litigation Overseen By Levin Papantonio
pharmaceutical investing Astellas and Pfizer's XTANDI Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer
pharmaceutical investing Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
pharmaceutical investing ACIP Votes to Expand Recommendation for Pfizer's RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
pharmaceutical investing Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24
pharmaceutical investing European Commission Approves Pfizer's RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
pharmaceutical investing ViiV Healthcare Announces Reimbursement for APRETUDE for HIV-1 Pre-Exposure Prophylaxis under the Non-Insured Health Benefits Program
Silver Crown Royalties Executes LOI with Kuya Silver for a Silver Royalty on the Bethania Silver Project
